DNA Repair Defects in IgA Deficiency
DNA Repair Defects in IgA Deficiency
批准号:
7532736
负责人:
Reuben S Harris
金额:
$22.43万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-08-15 至 2010-07-31
关键词:
AntibodiesAntibody FormationAntibody RepertoireBacteriaBacterial InfectionsBase Excision RepairsCellsCommon Variable ImmunodeficiencyCytosineDNADNA RepairDNA Repair GeneDNA Repair PathwayDNA SequenceDeaminationDefectDiagnosisDiseaseEnsureEuropeanEventExcisionExonsFamilyFamily StudyFrequenciesGastrointestinal tract structureGene FrequencyGenesHumanIgA DeficiencyIgEImmune responseImmunoglobulin AImmunoglobulin Class SwitchingImmunoglobulin Constant RegionImmunoglobulin GImmunoglobulin MImmunoglobulin Switch RecombinationImmunologic Deficiency SyndromesIndividualLaboratoriesMismatch RepairMutationNonhomologous DNA End JoiningPathway interactionsPatientsProcessPublic HealthPurposeRangeSerumSupplementationSystemTechnologyTestingTimeUracilVariantVirusactivation-induced cytidine deaminasebasecohortgenetic associationmembernew technologypathogenprogramsrespiratory
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): DNA Repair Defects in IgA Deficiency Immunoglobulin A deficiency (IgAD) is the most common primary immunodeficiency in humans, and it is characterized by the absence of serum IgA and an increased frequency of bacterial infections in the respiratory and gastrointestinal tracts. IgAD may develop over time into a more severe form of antibody deficiency, common variable immunodeficiency (CVID), and the two diseases can even co-exist in different members of the same family suggesting that they represent facets of the same underlying genetic defect(s). In order for IgA to be produced, the expressed heavy chain antibody isotype must be swapped for DNA sequences that encode IgA. This DNA level transaction is called class switch recombination (CSR) and it occurs between two so-called switch region sequences that reside upstream of the respective exons that encode the constant region of the antibody heavy chain. Recent studies have demonstrated that CSR is initiated by AID-catalyzed DNA cytosine deamination events and that the resulting uracil residues are recognized and processed by ubiquitous DNA repair systems such as base excision repair, mismatch repair, non-homologous end-joining and, most recently, single-strand annealing (alternative end-joining pathway). Defects in AID or uracil excision (UNG2) cause an immunodeficiency characterized by high levels of IgM at the expense of other antibody isotypes including IgA. We recently discovered variations in the mismatch repair gene MSH5 that associate with IgAD and CVID. Subsequent preliminary studies in our laboratories have revealed variations in other DNA repair genes that also associate with CVID and/or IgAD. This proposal will build on our prior studies by directly testing the hypothesis that multiple DNA repair defects also contribute to IgAD/CVID. The complete repertoire of known DNA repair genes from a minimum of 400 IgAD/CVID patients will be sequenced by a new technology called massively parallel DNA sequencing or 454 pyrosequencing. After computational analyses, candidate mutations will be validated by re-sequencing and by family studies using the largest IgAD/CVID patient cohort in the world. Key disease-associated mutations will be examined in cell-based systems for defects in DNA repair and in antibody gene diversification program. Overall, we anticipate significantly building upon our prior studies by demonstrating the involvement of several additional DNA repair factors in IgAD/CVID. PUBLIC HEALTH RELEVANCE: Antibodies are a crucial part of our immune response to pathogens such as bacteria and viruses. Recent evidence from many laboratories indicates that ubiquitous DNA repair factors help ensure an effective antibody response by facilitating the DNA level transactions that are required to generate a diverse and strong antibody repertoire. This proposal will determine the complete set of DNA repair gene sequences for more than 400 patients from one of the largest immunodeficiency disease cohorts in the world. We anticipate discovering several new factors that are essential for a robust antibody responses to pathogens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Midwest AViDD Center
-
批准号:10631659
-
项目类别:
-
资助金额:$45.68万
-
财政年份:2022
-
负责人:Reuben S Harris
-
依托单位:
Midwest AViDD Center
-
批准号:10522804
-
项目类别:
-
资助金额:$6643.12万
-
财政年份:2022
-
负责人:Reuben S Harris
-
依托单位:
Administrative-Core-001
-
批准号:10707575
-
项目类别:
-
资助金额:$9.59万
-
财政年份:2022
-
负责人:Reuben S Harris
-
依托单位:
Project 3: Pandemic Virus Protease Inhibitors
-
批准号:10522812
-
项目类别:
-
资助金额:$288.0万
-
财政年份:2022
-
负责人:Reuben S Harris
-
依托单位:
Core A: Administration
-
批准号:10522805
-
项目类别:
-
资助金额:$750.56万
-
财政年份:2022
-
负责人:Reuben S Harris
-
依托单位:
PROJECT 1
-
批准号:10474975
-
项目类别:
-
资助金额:$27.51万
-
财政年份:2019
-
负责人:Reuben S Harris
-
依托单位:
APOBEC MUTAGENESIS IN BREAST CANCER
-
批准号:10474974
-
项目类别:
-
资助金额:$175.12万
-
财政年份:2019
-
负责人:Reuben S Harris
-
依托单位:
PROJECT 1
-
批准号:10916617
-
项目类别:
-
资助金额:$8.05万
-
财政年份:2019
-
负责人:Reuben S Harris
-
依托单位:
APOBEC MUTAGENESIS IN BREAST CANCER
-
批准号:10738334
-
项目类别:
-
资助金额:$8.05万
-
财政年份:2019
-
负责人:Reuben S Harris
-
依托单位:
APOBEC MUTAGENESIS IN BREAST CANCER
-
批准号:10225387
-
项目类别:
-
资助金额:$171.35万
-
财政年份:2019
-
负责人:Reuben S Harris
-
依托单位:
PROJECT 1
-
批准号:9804091
-
项目类别:
-
资助金额:$27.01万
-
财政年份:2019
-
负责人:Reuben S Harris
-
依托单位:
APOBEC MUTAGENESIS IN BREAST CANCER
-
批准号:10676574
-
项目类别:
-
资助金额:$9.59万
-
财政年份:2019
-
负责人:Reuben S Harris
-
依托单位:
APOBEC MUTAGENESIS IN BREAST CANCER
-
批准号:9804090
-
项目类别:
-
资助金额:$165.65万
-
财政年份:2019
-
负责人:Reuben S Harris
-
依托单位:
PROJECT 1
-
批准号:10225388
-
项目类别:
-
资助金额:$34.78万
-
财政年份:2019
-
负责人:Reuben S Harris
-
依托单位:
2017 RNA Editing Gordon Research Conference and Gordon Research Seminar
-
批准号:9331005
-
项目类别:
-
资助金额:$0.3万
-
财政年份:2017
-
负责人:Reuben S Harris
-
依托单位:
(PQ2) HIV INFECTION, APOBEC UPREGULATION, AND CANCER MUTAGENESIS
-
批准号:9127434
-
项目类别:
-
资助金额:$21.93万
-
财政年份:2016
-
负责人:Reuben S Harris
-
依托单位:
(PQ2) HIV INFECTION, APOBEC UPREGULATION, AND CANCER MUTAGENESIS
-
批准号:9271943
-
项目类别:
-
资助金额:$18.22万
-
财政年份:2016
-
负责人:Reuben S Harris
-
依托单位:
Critical Interactions of APOBEC3s: Molecular Approaches to Novel HIV Therapies
-
批准号:8233319
-
项目类别:
-
资助金额:$193.3万
-
财政年份:2011
-
负责人:Reuben S Harris
-
依托单位:
Critical Interactions of APOBEC3s: Molecular Approaches to Novel HIV Therapies
-
批准号:8433365
-
项目类别:
-
资助金额:$199.77万
-
财政年份:2011
-
负责人:Reuben S Harris
-
依托单位:
Critical Interactions of APOBEC3s: Molecular Approaches to Novel HIV Therapies
-
批准号:8689415
-
项目类别:
-
资助金额:$2.03万
-
财政年份:2011
-
负责人:Reuben S Harris
-
依托单位:
海外基金